Massive asthma registry aims to unlock secrets of severe disease
NCT ID NCT06625216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a registry that will collect information from 5,000 people with severe asthma over time. The goal is to better understand the disease, how well patients follow their treatment plans, and how different biologic medications work in everyday life. Participants must be over 12 years old and have a confirmed diagnosis of severe asthma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2017
- Expected to finish
-
Feb 2037
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients older than 12 years, diagnosed for severe asthma by a specialist, according to the ERS/ATS criteria, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her GPs will be delivered.
- Ages
-
13 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. signed informed consent and privacy disclaimer; 2. age \> 12 years; 3. diagnosis of severe asthma according to the ERS/ATS criteria: 1. During treatment with: * High-dose ICS + at least one addistional controller (LABA, montelukast, or theophylline) or * Oral corticosteroids \>6 months/year 2. at least one of the following occurs or would occur if treatment would be reduced: * ACT \<20 or ACQ\>1.5 * At least 2 exacerbations in the last 12 months * At least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months * FEV1 \<80% (if FEV1/FVC below the lower limit of normal) Exclusion Criteria have not been considered in order to have a realistic view of severe asthma in real life.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
RECRUITINGRozzano, Milano, 20089, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle